HealthDay News — Baseline cortical atrophy measured within the early-onset Alzheimer disease (EOAD) signature, a set of predominantly parietotemporal regions showing greater atrophy in EOAD than in ...

The novel nitric oxide-donating prostaglandin analog met noninferiority endpoints vs latanoprost across two phase 3 trials.

Phase 3 CROSSING trial data show tezepelumab significantly improved histologic remission and dysphagia in patients aged 12 and older with eosinophilic esophagitis.

HealthDay News — Paternal exposure to valproate during sperm development is not associated with neurodevelopmental disorders (NDDs) in offspring, according to a study published online August 19 in ...

The FDA has approved Tivicay PD dispersible tablets for combination HIV-1 treatment in full-term neonates weighing at least 2kg.

Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver regeneration following surgical resection.

Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with ...

Clinicians may not agree on physical exam findings for youth with community-acquired pneumonia (CAP), according to a study published online August 20 in JAMA Ne ...

Imaavy (nipocalimab-aahu) is the first FcRn blocker approved to treat warm autoimmune hemolytic anemia in patients aged 12 years and older.

One phlebotomist can oversee up to 3 Aletta machines, directly helping to address the current phlebotomist shortage and long ...

HealthDay News — For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), the combination of anastrozole, palbociclib, ...

Interim phase 2 AZUR-1 trial results demonstrating sustained 12-month clinical complete responses support the priority review submission.